- Home
- CRWD vs BMY Comparison
CRWD vs BMY Comparison
Compare CRWD & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRWD | BMY |
|---|---|---|
| Founded | 2011 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.2B | 114.0B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRWD | BMY |
|---|---|---|
| Price | $390.39 | $60.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 44 | 14 |
| Target Price | ★ $546.37 | $59.93 |
| AVG Volume (30 Days) | 2.9M | ★ 11.4M |
| Earning Date | 03-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.18% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,953,624,000.00 | N/A |
| Revenue This Year | $23.94 | N/A |
| Revenue Next Year | $22.02 | N/A |
| P/E Ratio | ★ N/A | $17.26 |
| Revenue Growth | ★ 29.39 | N/A |
| 52 Week Low | $298.14 | $42.52 |
| 52 Week High | $566.90 | $63.33 |
Technical Indicators
Market Signals| Indicator | CRWD | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 49.00 | 63.79 |
| Support Level | $400.02 | $59.23 |
| Resistance Level | $432.85 | $61.30 |
| Average True Range (ATR) | 20.00 | 1.44 |
| MACD | 3.06 | 0.03 |
| Stochastic Oscillator | 77.81 | 77.57 |
Price Performance
Historical ComparisonAbout CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.